One explanation of this could be that TKIs are most efficacious when targeting tumor cells that express mutations in exons 19 and 21 of the EGFR kinase domain, which has been identified in various cancer types but has not yet been elucidated in GBM (14). The gene discussed is EGFR; the disease is neoplasm.